he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看离散地址
上一页:患有抑郁症的治疗方法有哪些
下一页:癫痫病比较好的外科手术方法是什么
- 2022-05-0220140606健康之南路视频全集:杨宇飞讲蛇酒的功效
- 2022-04-252013年国际抗癫痫Federation抗癫痫药使用指南
- 2019-04-20突发性癫痫患者如何预防才能避免
- 箕星宣布aficamten在中国获得突破性治疗药物认定
- 输卵管不能排卵吗?输卵管阻塞会导致不孕
- 最新研究 | 转移性乳腺癌一线化疗预后监测新突破
- 与甘精胰岛素相比,礼来替西帕肽能显著降低糖化血红蛋白(A1c)水平
- 癫痫猝死:凶手是谁?
- Blood:巨噬细胞Epo受体信号促进应激造血时红系的分化
- Eur Urol:随访 临床局部癌的根治性切除或观察扩展
- FDA 批准银屑病新药 ixekizumab
- P朋友应该多运动 但这些注意事项应该知道
- 日常生活中如何护理附睾畸形?
- 生发偏方 4种生发偏方使头发更浓密
- 必须走出移动医疗「只圈地 轻盈利」怪圈
- 幕后推手诱发男性更年期
- 炎症的原因是什么?
- 患者的饮食保健
- 一些脱发药物可以治疗年轻男性脱发或自杀
- 影响晨勃次数减少是否异常的四个因素,回答男性的问题
- 黑头怎么去?
- 预测癫痫患者再入院风险
- 为什么白带像豆腐渣?
- 阻碍性福的隐形杀手
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 继发性痛经
- 漳州市中医院灵活引才活力
- 结婚生子能有效缓解
- Neurology CP:1例巨细胞动脉炎
- BJU Int:寡转移性癌的可行性和安全性评估
- 癫痫病是怎样造成的 了解癫痫病的病变
- 2017癫痫病的最新放射治疗方法是什么
- 成都治疗癫痫病能够多少钱
- HIV的传染途径 6种途径成HIV传染重灾区(2)
- 癫痫病是没用 我们所不知道的危害
- 癫痫病还能有的疗法
- 去广州儿童医院|小儿癫痫的哮喘有哪些?
- 癫痫病有哪些疗法方法
- 癫痫病持续猝死的病因
- 癫痫病哪家医院疗法好
- 癫痫病的早期症状 有这些症状随便癫痫病
- 癫痫病的按摩病人
- 引起高血压癫痫病发作的病因有哪些?